SANA — Sana Biotechnology Share Price
0.000.00%
Last trade - 00:00- $371.29m
- $218.79m
- 18
- 25
- 37
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.48 | ||
| Price to Tang. Book | 7.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -59.86% | ||
| Return on Equity | -99.17% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
Directors
- Hans Bishop NEC (57)
- Steven Harr PRE (50)
- Nate Hardy CFO (45)
- Robin Andrulevich CHO
- James MacDonald EVP (46)
- Sunil Agarwal EVP (51)
- Christian Hordo EVP
- Richard Mulligan EVP (66)
- Edward Rebar SVP
- Joshua Bilenker IND (49)
- Douglas Cole IND (60)
- Robert Nelsen IND (57)
- Alise Reicin IND (60)
- Michelle Seitz IND (55)
- Mary Wilderotter IND (65)
- Patrick Yang IND (72)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 13th, 2018
- Public Since
- February 4th, 2021
- No. of Shareholders
- 40
- No. of Employees
- 194
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 225,024,899
- Address
- 188 East Blaine Street, Suite 400, SEATTLE, 98102
- Web
- https://sana.com/
- Phone
- +1 2067017914
- Auditors
- Ernst & Young LLP
Upcoming Events for SANA
Sana Biotechnology Inc Annual Shareholders Meeting
Q2 2025 Sana Biotechnology Inc Earnings Release
Similar to SANA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Sana Biotechnology share price?
As of Today at 23:02 UTC, shares in Sana Biotechnology are trading at $1.65. This share price information is delayed by 15 minutes.
How has the Sana Biotechnology share price performed this year?
Shares in Sana Biotechnology last closed at $1.65 and the price had moved by -80.02% over the past 365 days. In terms of relative price strength the Sana Biotechnology share price has underperformed the S&P500 Index by -81.22% over the past year.
What are the analyst and broker recommendations for Sana Biotechnology?
The overall consensus recommendation for Sana Biotechnology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sana Biotechnology dividend yield?
Sana Biotechnology does not currently pay a dividend.
Does Sana Biotechnology pay a dividend?
Sana Biotechnology does not currently pay a dividend.
When does Sana Biotechnology next pay dividends?
Sana Biotechnology does not currently pay a dividend.
How do I buy Sana Biotechnology shares?
To buy shares in Sana Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sana Biotechnology?
As of the previous close price of $1.65, shares in Sana Biotechnology had a market capitalisation of $371.29m.
Where are Sana Biotechnology shares listed?
Here are the trading details for Sana Biotechnology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SANA
What kind of share is Sana Biotechnology?
Based on an overall assessment of its quality, value and momentum Sana Biotechnology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sana Biotechnology share price forecast for 2025?
The analyst consensus target price for shares in Sana Biotechnology is $9.50. That is 475.76% above the last closing price of $1.65.
Analysts covering Sana Biotechnology currently have a consensus Earnings Per Share (EPS) forecast of -$0.89 for the next financial year.
Find out moreWhat is the trend in the Sana Biotechnology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sana Biotechnology. Over the past six months, its share price has underperformed the S&P500 Index by -56.77%.
As of the last closing price of $1.65, shares in Sana Biotechnology were trading -53.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sana Biotechnology PE Ratio?
The Sana Biotechnology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sana Biotechnology?
Sana Biotechnology's management team is headed by:
- Hans Bishop - NEC
- Steven Harr - PRE
- Nate Hardy - CFO
- Robin Andrulevich - CHO
- James MacDonald - EVP
- Sunil Agarwal - EVP
- Christian Hordo - EVP
- Richard Mulligan - EVP
- Edward Rebar - SVP
- Joshua Bilenker - IND
- Douglas Cole - IND
- Robert Nelsen - IND
- Alise Reicin - IND
- Michelle Seitz - IND
- Mary Wilderotter - IND
- Patrick Yang - IND